Louisiana has awarded business licenses to 775 companies that want to sell CBD products.
The state’s Office of Alcohol and Tobacco Control (ATC) received more than 1,000 permit applications after passage of a law outlining how retailers can sell products containing CBD. The ATC started the process in June.
Liquor stores, gas stations and CBD-specific shops were among the first businesses cleared to sell CBD.
Sellers must meet a lengthy list of requirements to receive licenses. The CBD products must carry scannable bar codes, QR codes or other information to verify the product’s certificate of analysis.
Smokable hemp products are banned in Louisiana.
Sales of beverages or food containing CBD are prohibited nationwide until the U.S. Food and Drug Administration (FDA) approves cannabinoids as an ingredient for human consumption.
The FDA began its scientific review of cannabis-derived products with a public hearing on May 31.
The agency said it will report on its progress by this fall, though it has made no promises about expanding CBD access.
While the Louisiana law ended uncertainty about whether CBD products can be sold in the state, some have said the regulations are overly burdensome.
In a study published this week in the journal Economic Inquiry, researchers found that the legalization of adult-use cannabis reduced opioid overdose deaths by 21%.
The study, carried out by economists at the University of Massachusetts and Colorado State University, found that legalization had “particularly pronounced effects for synthetic opioids” such as fentanyl.
“Our principal finding is that recreational marijuana access significantly decreases opioid mortality, with the most pronounced effects for synthetic opioids,” the researchers concluded. The effect “stems primarily from access via dispensaries rather than legality per se.”
Confirms Previous Studies
This week’s study backs up previous work on the question. A 2014 JAMA study found that states with medical marijuana laws saw 25% fewer deaths from opioid overdose compared to states without.
Last year two further studies found lower opioid prescription rates in legal states. A University of Kentucky researcher found a 6% lower rate of opioid prescriptions for pain in medical marijuana states, and a 12% lower opioid prescription rate in adult-use states. Meanwhile, researchers at the University of Georgia found that Medicare patients in medical marijuana states filled 14% fewer daily doses of opioids than patients in other states.
National Data, State Laws
In the latest study, economists from Massachusetts and Colorado examined mortality data from the Centers for Disease Control (1999 through 2017), and cross-checked that against data on the legal history of cannabis in each state. They then controlled for variables including income, race, ethnicity, sex, age, unemployment rates, and population.
The study’s authors point out that there were 47,600 deaths from opioids in the United States in 2017. A reduction of 21% would imply nearly 10,000 lives potentially saved.
“Our results have direct relevance for policy,” the researchers noted, “as they indicate that recent expansions to marijuana access have significant co-benefits in the form of reduced opioid mortality.”
“States with legal access to marijuana were far less affected by the opioid mortality boom of the past decade than those without,” they added. “Thus, our work provides important food for thought for state and federal authorities that continue to mull medical and/or recreational legalization of marijuana.”
Three Ways Cannabis Can Help
The Economic Inquiry study does not suggest the exact mechanisms by which cannabis helps reduce opioid deaths. But in a 2017 interview with Leafly, Canadian researcher Philippe Lucas laid out three primary avenues for amelioration.
Lucas suggested that pain patients might bypass the use of opioids altogether if physicians recommended trying medical cannabis first, rather than opioids first. If the cannabis provides sufficient relief, opioids would never need to come into the equation.
Second, cannabis may help patients using opioids to use fewer opioids or find more effective relief at lower dosage levels.
Third, cannabis may help those with an opioid dependency transition to replacement therapy with methadone.
The key, said Lucas, is a substitution effect that doesn’t have to be full and complete to be useful. Cannabis can be a therapeutic agent for some patients, and it can also act as a harm reduction agent for those who can’t completely stop their use of opioids. For those patients, cannabis may not be a complete substitute, but it may allow them to lower their opioid dosage and use and thereby stay alive.
read the original by: www.leafly.comat
One of Louisiana’s two medical marijuana growers is planning to do a “limited release” of the drug in May, a move aimed at getting treatments to those most in need amid demands from frustrated patients and pharmacy owners.
GB Sciences, the firm hired by LSU to run its marijuana-growing program, will take product it has already made in a temporary facility and release it to the state’s nine licensed pharmacies, GB Sciences Louisiana President John Davis said at a medical marijuana stakeholder meeting at the Louisiana Department of Agriculture offices in Baton Rouge.
After that, the company’s first full harvest of plants in the main facility that it just moved into won’t happen until August. It will take about a month to turn that into tinctures for sale to patients, Davis said.
“We want to go forward with the pharmacies with a limited release so we can get medicine to the most critically in-need patients,” Davis said.
“In general we would like to aim for May,” Davis said. “We know there are a lot of things involved with that,” he added. “We know it’s not going to supply the whole market.”
While GB Sciences is working to produce marijuana in its main facility, it will also be doing several harvests in the temporary pod, Davis said. After August, the company will be fully operating.
Patients and advocates packed the room Monday for the second meeting in a row to complain about repeated delays of the state’s medical marijuana program. Lawmakers passed legislation outlining the program in 2015, and set the program forward in 2016.
The Louisiana Association of Therapeutic Alternatives, which represents the state’s marijuana pharmacies and some doctors and patients, demanded product hit the shelves by May 15.
“We need this medication,” said Doug Boudreaux, head of the association and owner of a north Louisiana marijuana pharmacy. “We’re desperate for this medication.”
The Louisiana Board of Pharmacy selected nine pharmacies to sell marijuana in different regions throughout the state last spring. The board has since issued five of nine permits, while four others are awaiting inspections, said Carlos Finalet, general counsel for the pharmacy board.
While GB Sciences said it will release the drug in May, it is not clear who will be eligible to get access to the drug if it does become available then, as Davis made clear the amount of product would not be enough meet the demands of the entire market. The company will know soon how much product it will have for the May release, Davis said in an interview.
(Daily Advertiser)- LSU AgCenter Vice President Bill Richardson on Friday, March 8, 2019, fired back at Louisiana Agriculture Commissioner Mike Strain, calling Strain’s accusation that LSU is breaking the law by expanding its medical marijuana program “untrue” and “reckless.”
It’s the latest volley in an escalating feud between LSU AgCenter and Strain over the state’s fledgling cannabis program.
“Commissioner Strain made reckless and unsupported public accusations against the LSU AgCenter and GB Sciences Louisiana (LSU’s private partner) and threatened litigation,” Richardson said in a statement. “The allegations made by Commissioner Strain are simply untrue.”
The LSU AgCenter and Southern University AgCenter are the only ones who can legally grow the cannabis and produce the medicine, but Strain is the regulator who must sign off on their ability to proceed.
Though medical cannabis has been legal for years, it has yet to reach pharmacies and patients because of regulatory hurdles for LSU and its private partner GB Sciences. Southern’s program lags LSU because of early issues with its original private partner.
LSU contends Strain’s agency granted permission last week to proceed with moving the first crop from a small temporary growing pod into the main facility, but Strain said the move was based on a proposed contract with conditions that LSU refused to sign.
“They’ve fought the law every step of the way,” Strain said Monday in an exclusive interview with USA Today Network. “We’ve sent them a notice that they’re in violation of the law and we’ll proceed to a (court hearing).
“It’s crystal clear the movement of the plants was contingent on signing the memorandum of understanding,” said Strain, who said LSU AgCenter has resisted oversight from the beginning.
Richadson said the written offer from Strain to move the plants wasn’t reliant on signing the memorandum of understanding, insisting that was separate from the permission to move the plants.
“Relying on this written approval from the LDAF, the LSU AgCenter moved plant material into the two specific rooms on Friday, March 1, 2019,” Richards said. “The following Monday, an LDAF inspector issued a deficiency notice to the LSU AgCenter for doing what Commissioner Strain expressly approved the week before.”
Richardson said patients are suffering while he contends Strain is unnecessarily dragging his feet.
“Commissioner Strain’s actions are preventing thousands of patients from receiving the medical relief that they are anxiously awaiting and deserve,” Richardson said. “The LSU AgCenter calls on Commissioner Mike Strain to immediately allow this program to proceed, so that the patients of Louisiana can receive the medicine to which they are legally entitled.”
Strain has said LSU and GB Sciences are resisting providing information to Louisiana State Police for a required “suitability study,” or extensive background check that must be complete before Strain gives his blessing.
“Nothing is being done to hinder production of medical marijuana,” Strain said Friday in a statement. “The reason for issuing the Memorandum of Understanding (MOU) is to allow LSU AgCenter, the licensee, to supervise its subcontractor, GBSL, during hours of operation at the facility until the suitability determination is approved.
“LSU, the licensee, is deemed suitable by law, but GBSL, the subcontractor, is not. Suitability, as required by law, includes but is not limited to criminal, civil and financial background checks. In accordance with the MOU, LSU can supervise GBSL, the subcontractor, until the suitability process is completed and approved by the Louisiana Department of Agriculture and Forestry (LDAF).
“As of now, LSU-GBSL is not in compliance. Again, the LDAF cannot give LSU-GBSL the authority to break the law. However, LSU-GBSL can be in compliance to only move plant material into the requested rooms (Mother room and Vegetative room) by signing the MOU which was clearly a requirement as noted in the original letter dated February 28, 2019.”
Read the full article at klfy.com
Louisiana has had more than enough time to get its medical marijuana program up and running.
Not only does the state Department of Agriculture have guiding instructions in the form of the 2016 law regulating the effort, but it also has the collective experience of the many other states that have been down this road before us. And, most importantly, it has had two years to get it off the ground.
But still there are delays and confusion.
VIDEO: Watch Sen. Mitch McConnell use a pen made out of hemp to sign off on the final version of the Farm Bill…which legalizes hemp.
Southern University has given Advanced Biomedics until next Thursday to pay $2.15 million to the university and make progress on its medical marijuana growing operations, warning the company in a letter that otherwise the university would be “forced” to pick someone else to run its program.
Available Now for Interview and Analysis: DPA International Drug Policy Expert Hannah Hetzer
Tony Newman 646-335-5384
Hannah Hetzer 917-701-7060
In two separate rulings Wednesday, Mexico’s Supreme Court effectively set binding precedent that ends the country’s prohibition on marijuana use, possession and cultivation.
The following is a statement from Hannah Hetzer, Senior International Policy Manager at the Drug Policy Alliance:
“This is extraordinary because it is taking place in one of the countries that has suffered the most from the war on drugs. With marijuana already legal in Canada, now both of the US’s neighbors will have legal marijuana, making the US federal government’s prohibition of marijuana even more untenable.”
Hetzer is available for live and taped interviews in English and Spanish to provide analysis on this groundbreaking ruling, which paves the way for national legalization in Mexico.